Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ
Investing in Merck (NYSE:MRK) Three Years Ago Would Have Delivered You a 63% Gain
Merck's Net Cash Will See It Through -- Barrons.com
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
Merck (MRK.US) terminates Phase III study of PD-1+TIGIT combination therapy as first-line treatment for extensive-stage small cell lung cancer.
On August 8, Merck (MRK.US) announced that, following the recommendation of an independent data monitoring committee (DMC), the development of KeyVibe-008 in Phase III will be terminated.
